Former Sanofi CEO Brandicourt takes board seat at RNAi therapy maker Alnylam

Sanofi CEO
Olivier Brandicourt will take the Alnylam board seat eight months after departing Sanofi. (Sanofi)

When former Sanofi CEO Olivier Brandicourt handed the reins to Paul Hudson in June, it marked a turning point after a tumultuous period at the French drugmaker. Now eight months out of a job, Brandicourt is now taking a boardroom seat at a much younger drugmaker with the opportunity for big growth in the coming years.

Alnylam, the maker of ultra-pricey RNAi therapies Onpattro and Givlaari, named Brandicourt to its board of directors in a move that will add "invaluable perspective" to the drugmaker's leadership team, the company said in a release.

Brandicourt, Sanofi head from 2015 to 2019 and a former CEO at Bayer HealthCare, left Sanofi in June as part of a planned transition of leadership to Hudson. Prior to Bayer, Brandicourt spent 13 years at Pfizer, including a stint as president and general manager of the emerging markets and established products units. 

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

With Brandicourt coming on board, Alnylam will say goodbye to director Paul Schimmel, a professor emeritus at the Massachusetts Institute of Technology who has served on Alnylam's board since its founding in 2002, the company said. Following his retirement after Alnylam's 2020 shareholder meeting, Schimmel will remain on the company's scientific advisory board.

RELATED: Headed for the exit: Sanofi CEO Brandicourt to retire, Novartis' Hudson steps in

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.